Loading...
By Amy Orciari Herman
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
Researchers have found a way to expedite new cancer treatments for some patients: enroll them in small studies where they are treated based on their genetic mutations, not the organ where their cancer originated.
These so-called "basket studies," the New York Times reports, enroll patients with wide varieties of cancer who share genetic mutations that may respond to certain drugs. There are no control groups.
The Times describes one basket study in which 18 patients with Erdheim-Chester disease or Langerhans disease received a melanoma drug that targets a BRAF mutation. In 14 patients, the tumors stopped growing, shrank, or disappeared altogether. The remaining four have just begun treatment.
This spring, the National Cancer Institute will begin its Match program, which will screen tumor samples from thousands of U.S. patients for about a dozen mutations. Those who screen positive may enroll in studies of drugs directed at those mutations.
The FDA says it could approve treatments based on data from basket studies alone, the Times reports.
Comment
LINK(S):
New York Times story (Free)
Background: Physician's First Watch coverage of President Obama's precision medicine initiative (Free)